Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel: +47 21 07 81 60
E-mail:

Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2022 meeting (3 year revision) are listed below. See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2022.

ATC code	ATC level name (INN/generic name)	DDD	Unit	Adm.route

A04AD11	nabilone	3	mg	O
A10BJ06	semaglutide	0.11	mg	P
A16AB17	cerliponase alfa	21	mg	P
A16AX09	glycerol phenylbutyrate	15	g	O
G03XX01	prasterone	6.5	mg	V
G04BX15	pentosan polysulfate sodium	0.3	g	O
J01AA14	sarecycline	0.1	g	O
J01AA15	omadacycline	0.3	g	O
J01AA15	omadacycline	0.1	g	P
J01DD64	cefpodoxime and beta-lactamase inhibitor	0.4 ¹⁾	g	O
J01MA12	levofloxacin	0.24	g	Inhal.solution
J04AA03	calcium aminosalicylate	15	g	O
J04AB06	enviomycin	1	g	P
J05AB03	vidarabine	0.7	g	P
J05AG06	doravirine	0.1	g	O
J05AH03	peramivir	0.6	g	P
J05AH04	laninamivir	40	mg	Inhal.powder
J05AP06	asunaprevir	0.2	g	O
J05AP10	elbasvir	50	mg	O
J05AP11	grazoprevir	0.1	g	O
J05AX25	baloxavir marboxil	40	mg	O
J05AX26	amenamevir	0.4	g	O
J05AX27	favipiravir	1.6	g	O
L02BB05	apalutamide	0.24	g	O
L04AB07	opinercept	7	mg	P
L04AC12	brodalumab	15	mg	P
M03BX03	pridinol	6	mg	O
M04AB05	lesinurad	0.2	g	O
N02CD01	erenumab	2.5	mg	P
N02CD02	galcanezumab	4	mg	P
N02CD03	fremanezumab	7.5	mg	P
P01CA03	fexinidazole	1.44	g	O
V03AE10	sodium zirconium cyclosilicate	7.5	mg	O

1) Refers to cefpodoxime

Last updated: 2021-12-08